Trade Specialist Group
For the unbureaucratic financing of innovations
In addition to the rising pressure on costs and pricing, increasing regulatory density is creating additional problems for medtech companies. The Trade Specialist Group is committed to reducing bureaucracy and maintaining a pragmatic and efficient model for the approval and reimbursement of new products. (For more information please click link below picture)
Image source: Fotolia
Image source: Fotolia

More information in German / French

Specialist Group Information


  • Secure timely patient access to new medical products;
  • Promote accelerated financing for innovation (ex. lean processes) in both outpatient and inpatient settings;
  • Advocate for the principle of trust when it comes to reimbursement;
  • Increase the regard for medtech-specific properties;


  • Highlight the benefits and performance of high-quality medical technology for the health care system and the economy;
  • Provide support for tariff revisions, e.g. MiGeL;
  • Represent the Association in the Federal Commission for General Services and Principle Issues (ELGK) and in the Federal Commission for Analysis, Means, and Objects (EAMGK).
  • Participate in the revision of the HTA processes" Re-evaluation" by the Federal Office of Public Health (BAG)


  • 9 members
  • Lead: Beat Egli (Zimmer Biomet)


Swiss Medtech - Office